SCHEMBL15345113

SCHEMBL15345113

Cc1ccnc(-c2ccc3ccc(=O)n(C)c3c2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.46
CCR5 P51681 1/20 0.46
CCR8 P51685 1/20 0.46
CYP2A6 P11509 1/20 0.45
BRPF1 P55201 3/20 0.44
CA12 O43570 1/20 0.44
BRD4 O60885 1/20 0.44
CA9 Q16790 1/20 0.44
KAT2B Q92831 1/20 0.44
BRD9 Q9H8M2 1/20 0.44
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
GLA P06280 1/20 0.37
MAPT P10636 1/20 0.37
IRAK4 Q9NWZ3 3/20 0.37
DYRK1A Q13627 1/20 0.37
CNR1 P21554 1/20 0.36
SYK P43405 2/20 0.36
ABL1 P00519 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15344977 0.90 BRPF1 (0.49) CCR1CCR5CCR8CYP2A6BRPF1
SCHEMBL15341936 0.83 BRPF1 (0.40) BRPF1CA12BRD4CA9KAT2B
SCHEMBL31743113 0.82 CA12 (0.51) CYP2A6BRPF1CA12BRD4CA9
SCHEMBL15345057 0.79 MAPK14 (0.54) CCR1CCR5CCR8CYP2A6BRPF1
SCHEMBL1119899 0.77 BRPF1 (0.59) CYP2A6BRPF1CA12BRD4CA9
SCHEMBL31743104 0.75 HTR6 (0.54) BRPF1CA12BRD4CA9KAT2B
SCHEMBL15344155 0.75 IRAK4 (0.48) CCR1CCR5CCR8CYP2A6IRAK4
SCHEMBL15341747 0.74 BRPF1 (0.44) BRPF1CA12BRD4CA9KAT2B
SCHEMBL15345049 0.73 CCR1 (0.46) CCR1CCR5CCR8CYP2A6KDM4E
SCHEMBL15345112 0.73 CA12 (0.49) CCR1CCR5CCR8CYP2A6CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3070081-B1 BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION GILEAD SCIENCES INC (US) 2018-02-28 EP disclosed
US-20160015690-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-21 US disclosed
US-8987250-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-03-24 US disclosed
US-20130281433-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015690-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 CCR1 106/4885CCR5 3/4885CCR8 125/4885
US-20130281433-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 CCR1 106/4885CCR5 3/4885CCR8 125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.